| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
23006 |
| Drug |
Icosapent ethyl |
| Brand |
Vazkepa® |
| Indication |
Icosapent ethyl (Vazkepa®) is indicated to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (?150 mg/dL [?1.7 mmol/L] and established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor. |
| Rapid review commissioned |
10/02/2023 |
| Rapid review completed |
10/03/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of icosapent ethyl compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
28/03/2023 |
| Pre-submission consultation with Applicant |
20/06/2023 |
| Full submission received from Applicant |
01/11/2023 |
| Preliminary review sent to Applicant |
18/09/2024 |
| NCPE assessment re-commenced |
25/10/2024 |
